According to a new report published by OG Analysis, the global HIV Diagnostics Market is valued at USD 6.0 billion in 2026 and is projected to reach USD 12.78 billion by 2034, expanding at a CAGR of 9.9% during the forecast period. The report uses 2025 as its base year and 2026 as the estimated year. The full report, including detailed segmentation, regional analysis.

Market Overview

The market is a core segment of infectious-disease diagnostics, supporting HIV screening, diagnosis of acute infection, confirmatory testing, early infant diagnosis, treatment initiation, viral-load monitoring, blood safety, and long-term disease management. Demand spans rapid antibody tests, fourth-generation antigen/antibody assays, PCR and nucleic-acid testing, self-test kits, confirmatory assays, CD4 monitoring, and laboratory automation. Market growth is being supported by broader screening programs, decentralized point-of-care testing, self-testing, community-based delivery, antenatal testing, and the need for faster linkage to treatment and prevention. Product differentiation increasingly depends on early-infection sensitivity, turnaround time, ease of use, self-test suitability, multiplex capability, quality assurance, procurement eligibility, and compatibility with public-health testing algorithms.

Key Market Insights

●       The market size is USD 6.0 billion in 2026 and is forecast to reach USD 12.78 billion by 2034 at a 9.9% CAGR, supported by expanding screening, earlier diagnosis, self-testing, point-of-care access, and viral-load monitoring.

●       North America leads regional market share at 31% in 2026, while Asia-Pacific remains a high-opportunity growth region as governments and health systems expand affordable rapid tests, self-testing, maternal screening, and decentralized testing pathways.

●       Rapid Testing is the leading technology with a 57% share, reflecting broad use in community programs, public-health screening, antenatal care, self-testing, and same-day point-of-care diagnosis.

●       Diagnostic Laboratories lead the end-user mix with a 61% share in the dedicated segment analysis, supported by centralized testing volumes, PCR and NAT capability, confirmatory workflows, automated immunoassays, and viral-load monitoring.

●       Global production in 2026 is estimated at approximately 850 million test-equivalent units, with a blended average selling price of about USD 5 per test-equivalent unit; pricing ranges from low-cost rapid screening formats to higher-value molecular and viral-load assays.

Market Dynamics

●       Driver: Expanding national screening programs, routine opt-out testing, and earlier diagnosis initiatives are increasing demand across hospitals, laboratories, community networks, pharmacies, and public-health programs.

●       Driver: Rapid tests, HIV self-testing, and decentralized point-of-care formats are broadening access by reducing dependence on centralized laboratories and enabling same-day or private testing.

●       Opportunity: Integrated dual and multiplex diagnostics that combine HIV with syphilis, hepatitis B, or other infections can improve maternal-health and public-health workflows while expanding addressable testing volumes.

●       Restraint: Public-health funding volatility, donor-program disruption, tender dependence, and uneven procurement can affect test volumes and supply continuity, particularly in high-burden low- and middle-income countries.

●       Restraint: Very-early infection can remain difficult to detect with antibody-based methods, sustaining the need for confirmatory immunoassay and molecular testing and increasing algorithm complexity.

●       Opportunity: Over-the-counter self-tests, oral-fluid testing, pharmacy distribution, digital linkage-to-care, and home-based testing can expand consumer access and reduce stigma-related barriers.

●       Opportunity: Localized manufacturing, regional packaging, quality-assured low-cost rapid tests, and partnerships with public-health systems can strengthen supply resilience and improve access in Africa, Asia, and Latin America.

Browse for more information

https://www.oganalysis.com/industry-reports/hiv-diagnostics-market

Market Segmentation

The market is segmented by product type, end user, technology, distribution channel, and region. By product type, the industry report covers Test Kits and Reagents. By end user, demand is concentrated in Diagnostic Laboratories and Hospitals, with Diagnostic Laboratories leading at 61% in the dedicated segment analysis and Hospitals accounting for 39%. By technology, the market includes PCR and Rapid Testing, with Rapid Testing holding a 57% share in 2026. Distribution is segmented into Online and Offline channels, with Offline accounting for 82% due to hospital procurement, diagnostic-laboratory purchasing, government tenders, NGO supply chains, and medical-device distributors. Regionally, the market forecast covers North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America.

Regional Insights

●       North America: The region leads with a 31% share in 2026, supported by mature laboratory infrastructure, routine screening policies, molecular testing capacity, strong rapid-test adoption, and expanding consumer access to home and self-testing.

●       Asia Pacific: The region is a high-opportunity growth market where affordable rapid tests, self-test kits, integrated maternal-health screening, and point-of-care formats are helping expand access across diverse public-health and primary-care settings.

●       Europe: The region remains a quality-driven market where growth is tied to reducing late diagnosis, widening community and pharmacy access, expanding self-testing, and maintaining high-quality laboratory confirmation and molecular workflows.

●       Latin America & Middle East and Africa: These regions offer substantial public-health opportunity through low-cost rapid tests, self-testing, antenatal dual-testing formats, decentralized delivery, donor and government procurement, and more resilient local or regional supply partnerships.

Competitive Landscape

The market includes multinational in vitro diagnostics companies, molecular-platform providers, rapid-test developers, self-testing specialists, and suppliers focused on confirmatory and disease-monitoring workflows. Competitive positioning depends on analytical sensitivity, early-detection performance, regulatory approvals, WHO prequalification, point-of-care usability, self-test convenience, turnaround time, installed laboratory platforms, procurement eligibility, and access to public-health channels. Leading companies compete across rapid screening, automated fourth-generation immunoassays, PCR and viral-load testing, CD4 monitoring, oral-fluid self-testing, and confirmatory assays, while partnerships and localized distribution are becoming more important in decentralized and high-burden markets.

Some of the key players operating in the market include Abbott Laboratories, Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific Inc., bioMérieux SA, Grifols S.A., Becton, Dickinson and Company (BD), Hologic Inc., QIAGEN N.V., Trinity Biotech, OraSure Technologies, Chembio Diagnostics (BioSynex), Bio-Rad Laboratories, Alere Inc., Sysmex Corporation, Mylan N.V., Getein Biotech Inc., Guangzhou Wondfo Biotech, and Beckman Coulter (Danaher).

Recent Developments

●       June 2026: bioLytical Laboratories donated 4,200 INSTI HIV Self Tests for National HIV Testing Day activities at Walgreens, marking its first U.S. donation of the self-test and expanding consumer-facing access to rapid HIV screening.

●       April 2026: bioLytical Laboratories announced that the INSTI HIV Self Test joined the Together TakeMeHome program, supporting free national distribution of HIV self-tests directly to individuals across the United States.

●       February 2026: OraSure Technologies announced that its OraQuick HIV Self-Test received a Health Canada license, making it Canada's first oral HIV self-test and enabling HIV-1/HIV-2 antibody testing from an oral swab with results in as little as 20 minutes.

●       October 2025: bioLytical Laboratories announced U.S. FDA approval of the INSTI HIV Self Test for over-the-counter use, introducing a fingerstick self-test capable of producing results in approximately one minute.

●       July 2025: WHO prequalified Abbott's Determine Antenatal Care Panel, the first bundled rapid diagnostic panel designed to detect HIV, hepatitis B, and syphilis, supporting integrated screening in maternal and public-health programs.